There is a huge need for innovative solutions in healthcare. In the Health, we include ideas covering areas such as medtech, diagnostics, biotech and e-health. STING companies develop smart and cost-effective products or services which improve and increase the quality of healthcare. In Biotech, the companies produce effective solutions within, for example, the research industry so we can bring about new and better products faster and with higher quality. More and more life science innovations contain an ICT element and most of the STING companies, but not all, have a B2B business model. 

Business coaches

Our Health coaches have worked in the life science and medtech industry for 20-25 years in both small startups and large multinational companies, and in various roles. Olof has built up new innovative companies from the bottom up and also worked with Laboriatories and Glaxo Wellcome (later GlaxoSmithKline). He has carried out a number of launches both nationally and internationally. Gisela has started and built up a laboratory company acquired by Capio. She has also worked with seed and venture capital investments at early-stages. Both coaches are active outside STING as board members at small and medium-sized companies. Please contact Olof or Gisela if you have an idea within the area of Health.


We work together with many external partners who can help the STING companies to progress in various business areas. Within Health we have valuable collaborations with, for example, Astra Tech, Elekta, Gambro and Karolinska Institutet. You can read about all of our partners here.

STING companies

Here are some of the many exciting startups which STING is coaching in Health: Antrad has produced a method for thawing blood plasma in five minutes, a procedure which otherwise takes 20-40 minutes. Bioservo develops muscle-strengthening devices and the first product is a glove which strengthens grip, Chundsell develops a diagnostic method meaning that up to 70% of prostate cancer patients will not need to undergo radical treatments, and Single Technologies has produced advanced methods for studying signalling networks in living cells opening up the possiblities to make completely new types of medicines and hopefully also to reduce the number of pointless clinical trials.

Programs and events